1. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Issue 9 (13th May 2021) Authors: Mease, Philip J; Chohan, Saima; Fructuoso, Ferran J Garcia; Luggen, Michael E; Rahman, Proton; Raychaudhuri, Siba P; Chou, Richard C; Mendelsohn, Alan M; Rozzo, Stephen J; Gottlieb, Alice Journal: Annals of the rheumatic diseases Issue: Volume 80:Issue 9(2021) Page Start: 1147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗